HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.

香港，2024年3月6日/PRNewswire/--即使形势不断变化，技术创新仍然是生物制药公司长期发展的最关键组成部分。这种持续的创新使公司保持最新，并促进了研发的发展和商业化的成功。

Recently, Viva Biotech's portfolio companies have new updates. Keep reading for more details..

最近，Viva Biotech的投资组合公司有了新的更新。继续阅读以了解更多详细信息。。

AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers

AceLink Therapeutics宣布公布在健康志愿者中评估AL01211的1期临床试验数据

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy.

加利福尼亚州纽瓦克——由Viva BioInnovator（VBI）投资和孵化的AceLink Therapeutics，Inc.是一家临床阶段的生物制药公司，开发下一代口服底物减少疗法（SRT）。最近，他们宣布，他们在健康志愿者中进行的AL01211第一阶段研究的结果已发表在同行评审的《药物开发中的临床药理学》杂志上，该杂志是美国临床药学学院的一本杂志。

AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease..

AL01211是一种有效的口服葡萄糖神经酰胺合酶（GCS）抑制剂，正在开发用于治疗法布里病和1型戈谢病。。

In the published Phase 1 study, AL01211 was evaluated with a single ascending dose arm and a multiple ascending dose arm to determine the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects in healthy volunteers. Overall, AL01211 was generally safe and well-tolerated with no serious adverse events.

在已发表的第一阶段研究中，使用单次递增剂量组和多次递增剂量组对AL01211进行了评估，以确定健康志愿者的安全性，药代动力学（PK）和药效学（PD）效应。总体而言，AL01211通常是安全的，耐受性良好，没有严重的不良事件。

At a 30 mg dose level, plasma glucosylceramide and globotriaosylceramide were reduced from baseline levels by 78% and 52%, respectively, thus supporting AL01211's further clinical development..

在30 mg剂量水平下，血浆葡萄糖神经酰胺和球糖神经酰胺分别比基线水平降低了78%和52%，从而支持了AL01211的进一步临床开发。。

Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke

Basking Biosciences宣布结束5500万美元的融资，以加速首次可逆性溶栓治疗缺血性中风的临床开发

Columbus, Ohio – Jan. 30, 2024 – Basking Biosciences (Basking), invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke. Recently they announced the close of a $55 million financing. New investor ARCH Venture Partners led the round, with participation from additional new investors Insight Partners, Platanus, Solas BioVentures and RTW Investments, as well as existing investors Longview Ventures, Rev1 Ventures and The Ohio State University.

俄亥俄州哥伦布市–2024年1月30日–由Viva BioInnovator（VBI）投资和孵化的Basking Biosciences（Basking）是一家临床阶段的生物制药公司，正在开发一种治疗中风的新型急性溶栓疗法。最近，他们宣布结束5500万美元的融资。新投资者ARCH Venture Partners领导了这一轮投资，其他新投资者Insight Partners、Platanus、Solas BioVentures和RTW Investments以及现有投资者Longview Ventures、Rev1 Ventures和俄亥俄州立大学也参与了这一轮投资。

Steven Gillis, Ph.D., Managing Director of ARCH Venture Partners will serve as Chairman of Basking's Board of Directors. Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech..

ARCH Venture Partners董事总经理Steven Gillis博士将担任Basking董事会主席。此前，该公司已经完成了540万美元的种子融资，投资者包括Rev1 Ventures、Broadview Ventures和Viva Biotech。。

Basking will utilize the proceeds to accelerate clinical development of BB-031, a first-in-class, reversible RNA aptamer targeting von Willebrand Factor (vWF), engineered for rapid onset and short duration of effect.

Basking将利用这些收益加速BB-031的临床开发，BB-031是一种靶向von Willebrand因子（vWF）的一流可逆RNA适体，设计用于快速起效和短效期。

Technoderma Medicines Secures Multi-Million Dollar Pre-B Round Financing , and Its Globally First-in-Class New Drug TDM-105795 for Treating Androgenetic Alopecia Completes Phase 2a Clinical Trial Successfully and Completes Phase I Dose Escalation Clinical Trial of TDM-180935 for Eczema/Dermatitis Indication.

Technoderma Medicines获得了数百万美元的B轮前融资，其用于治疗雄激素性脱发的全球一流新药TDM-105795成功完成了2a期临床试验，并完成了TDM-180935用于湿疹/皮炎适应症的I期剂量递增临床试验。

According to VBDATA.CN on January 15th, Technoderma Medicines, Inc. ('Technoderma Medicines'), a clinical-stage company focused on new drug development for skin diseases that was incubated and invested by Viva BioInnovator, announced that it has recently completed a Pre-B round financing of tens of millions of RMB.

根据VBDATA。CN 1月15日，由Viva BioInnovator孵化和投资的专注于皮肤病新药开发的临床阶段公司Technoderma Medicines，Inc.（“Technoderma Medicines”）宣布，它最近完成了数千万元人民币的前B轮融资。

This round of financing raised will be used for subsequent clinical development of the hair loss project and Phase 2 clinical trials (China and U.S. Phase 2a) of the atopic dermatitis project. Subsequently, on February 5th, Terkro was pleased to announce that the first Phase 2 clinical trial (NCT05802173) of the topical formulation TDM-105795 for the treatment of androgenetic alopecia (AGA) was successfully completed..

这一轮融资将用于脱发项目的后续临床开发和特应性皮炎项目的2期临床试验（中国和美国2a期）。随后，2月5日，特克罗高兴地宣布，用于治疗雄激素性脱发（AGA）的局部制剂TDM-105795的第一阶段2临床试验（NCT05802173）已成功完成。。

On Dec. 4th, 2023, Technoderma Medicines announced that it has completed a Phase I clinical trial (NCT05525468) of TDM-180935 topical ointment for the treatment of atopic dermatitis/eczema. The results all met expectations.

2023年12月4日，Technoderma Medicines宣布已完成TDM-180935外用软膏治疗特应性皮炎/湿疹的I期临床试验（NCT05525468）。结果都达到了预期。

Full-Life Technologies Announces USD $47.3 million Series B Financing, and Broke Ground for GMP Manufacturing Facility in Belgium

Full Life Technologies宣布B系列融资4730万美元，并在比利时破土动工建设GMP生产设施

Shanghai, Gembloux, Belgium, and Heidelberg, Germany - Jan. 4, 2024 - Full-Life Technologies ('Full-Life'), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities.

2024年1月4日，比利时的上海和德国的海德堡-全面整合的全球放射治疗公司Full-Life Technologies（“Full-Life”）今天宣布完成6330万美元的融资，其中包括4730万美元的B系列股权融资和1600万美元的贷款。

The financing will advance development of the Company's radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDCTM. With completion of such financing, Full-Life has secured more than $110 million funding since its inception in August 2021, including equity financing, loan facilities, and government subsidies..

该融资将推动该公司放射性药物管道和制造能力的发展，并优化其专有发现平台UniRDCTM。随着这些融资的完成，Full Life自2021年8月成立以来已获得超过1.1亿美元的资金，包括股权融资、贷款和政府补贴。。

On Dec. 8th, 2023, Full-Life aslo announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals. This strategic investment aims to advance Full-Life's end-to-end solution by enhancing its radiopharmaceutical production capabilities at a key logistical hub to ensure the timely supply and delivery to patients worldwide..

2023年12月8日，Full Life aslo宣布在比利时Gembloux为放射性药物建造符合良好生产规范（GMP）的新生产设施。这项战略投资旨在通过增强其在关键物流中心的放射性药物生产能力来推进Full Life的端到端解决方案，以确保及时向全球患者提供和交付。。

VivaVision Receives Funding from the 'Enterprise Support Scheme' of Hong Kong's Innovation and Technology Commission and is Named on Hurun Global Cheetah Index 2023

VivaVision获得香港创新科技委员会“企业支持计划”的资助，并被列入2023年胡润全球猎豹指数

Vivavision's subsidiary, which is a company focused on differentiated and globally novel ophthalmic innovative drugs and was incubated and invested in by Viva BioInnovator (VBI), recently announced that its innovative retinal drug VVN481 has successfully obtained funding from Hong Kong's Innovation and Technology Commission's  'Enterprise Support Scheme' (ESS—Hong Kong-Israel R&D Cooperation Programme).

Vivavision的子公司是一家专注于差异化和全球新型眼科创新药物的公司，由Viva BioInnovator（VBI）孵化和投资，最近宣布，其创新性视网膜药物VVN481已成功获得香港创新科技委员会“企业支持计划”（ESS-香港-以色列研发合作计划）的资助。

This funding will be used to advance the preclinical R&D work of this pipeline to accelerate its progress towards clinical stage. In addition, VivaVision was also  named on  Hurun Global Cheetah Index 2023..

这笔资金将用于推进该管道的临床前研发工作，以加速其向临床阶段的进展。此外，VivaVision还被列入胡润全球猎豹指数2023。。

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

Absci宣布与阿斯利康合作，推进AI驱动的肿瘤学候选人

VANCOUVER, Wash., Dec. 04, 2023 -- Absci Corporation (Nasdaq: ABSI), invested by Viva BioInnovator (VBI), is a leader in generative AI antibody discovery.They announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target.

温哥华，华盛顿，2023年12月4日——由Viva BioInnovator（VBI）投资的Absci公司（纳斯达克：ABSI）是产生性AI抗体发现的领导者。他们宣布与全球生物制药公司阿斯利康（AstraZeneca）合作，以提供针对肿瘤靶标的AI设计抗体。

This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate. It is reported that the agreement includes an upfront commitment, R&D funding and milestone payments, etc., with a total with a total amount up to $247 million..

这项合作将Absci的Integrated Drug Creation™平台与阿斯利康在肿瘤学方面的专业知识相结合，旨在加速发现潜在的新癌症治疗候选药物。据报道，该协议包括前期承诺、研发资金和里程碑付款等，总金额高达2.47亿美元。。

About AceLink Therapeutics, Inc.

关于AceLink Therapeutics，Inc。

Founded in 2018, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address genetic diseases with high unmet needs. The company's initial focus is to develop novel therapeutics for Fabry disease. For more information, please visit www.acelinktherapeutics.com..

AceLink Therapeutics成立于2018年，是一家创新的生物制药初创公司，专注于开发安全有效的药物，以解决未满足需求的遗传疾病。该公司最初的重点是开发针对法布里病的新型疗法。欲了解更多信息，请访问www.acelinktherapeutics.com。。

About Basking Biosciences

关于Basking Biosciences

Basking Biosciences, a clinical-stage biopharmaceutical company, was founded to solve the biggest need in acute thrombosis – for a rapid-onset, short-acting thrombolytic drug capable of reopening blocked arteries, and whose activity can be quickly reversed in the event of a bleeding complication. Leveraging RNA aptamer technology, our lead drug candidate, BB-031, targets von Willebrand Factor (vWF), an important structural component of blood clots and driver of the clotting process, and is designed to be safer, more effective, and able to greatly expand the population receiving acute revascularization therapy..

Basking Biosciences是一家临床阶段的生物制药公司，成立的目的是解决急性血栓形成的最大需求-一种快速起效的短效溶栓药物，能够重新打开阻塞的动脉，并且在出血并发症发生时其活性可以迅速逆转。利用RNA适体技术，我们的主要候选药物BB-031靶向血管性血友病因子（vWF），它是血栓的重要结构成分和凝血过程的驱动因素，旨在更安全，更有效，并能够大大扩大接受急性血运重建治疗的人群。。

For more information, visit BaskingBiosciences.com.

有关更多信息，请访问BaskingBiosciences.com。

About Technoderma Medicines

关于Technoderma Medicines

Technoderma Medicines, Inc. is a privately held clinical stage biopharmaceutical company. The Company was originally located in Jiaxing Xiuzhou Biomedicine Guoqian Park, China, and recently relocated to Chengdu Biomed Town, Chengdu, Sichuan Province, China. Its current core programs focus on development of innovative therapies for Androgenetic Alopecia, Atopic Dermatitis, Psoriasis and Lupus Erythematosus.

Technoderma Medicines，Inc.是一家私营临床阶段生物制药公司。该公司最初位于中国嘉兴秀洲生物医药国前公园，最近迁至中国四川省成都市成都生物医药城。其目前的核心项目侧重于开发雄激素性脱发，特应性皮炎，牛皮癣和红斑狼疮的创新疗法。

Its 'first-in-class' small molecule thyromimetic drug candidate TDM-105795 for Androgenetic Alopecia is currently in Phase 2a clinical testing. Technoderma's novel JAK1/TYK2 inhibitor TDM-180935 for Atopic Dermatitis is now in Phase 1 clinical testing. The pipeline targets dermatologic indications..

其用于雄激素性脱发的“一流”小分子拟甲状腺药物候选TDM-105795目前正在进行2a期临床测试。Technoderma针对特应性皮炎的新型JAK1/TYK2抑制剂TDM-180935目前正在进行1期临床测试。该管道针对皮肤科适应症。。

About Full-Life Technologies

关于全寿命技术

Full-Life Technologies Limited ('Full-Life') is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients.

Full-Life Technologies Limited（“Full-Life”）是一家全面整合的全球放射治疗公司，在比利时、德国和中国开展业务。我们寻求拥有放射性药物研发、生产和商业化的整个价值链，以便为患者带来临床影响。

The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development..

该公司计划通过针对未来治疗的创新研究，解决目前影响放射性药物的核心问题。我们由一群快速发展的企业家和科学家组成，他们在生命科学以及放射性同位素研究和临床开发方面有着良好的业绩记录。。

About VivaVision Biotech

关于VivaVision Biotech

VivaVision is a clinical stage pharmaceutical company focused on best-in-class and first-in-class therapies for ocular diseases. VivaVision's current pipeline includes VVN001 for treating dry eye syndrome, VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious ocular inflammation of Uveitis.

VivaVision是一家临床阶段制药公司，专注于一流和一流的眼部疾病治疗。VivaVision目前的管道包括用于治疗干眼症的VVN001，用于治疗青光眼或高眼压的VVN539，以及用于治疗葡萄膜炎非感染性眼部炎症的VVN461。

VivaVision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases. For more info, visit www.vivavisionbio.com..

VivaVision还致力于发现和开发用于治疗其他前后眼病的新型疗法。欲了解更多信息，请访问www.vivavisionbio.com。。

About Absci

关于Absci

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit.

Absci是一家生成性人工智能药物创建公司，它将人工智能与可扩展的湿实验室技术相结合，为患者更快地创建更好的生物制剂。我们的Integrated Drug Creation™平台通过同时优化对开发和治疗益处都很重要的多种药物特性，释放了加速临床时间和增加成功概率的潜力。

With the data to learn, the AI to create, and the wet lab to validate, Absci can screen billions of cells per week, allowing it to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci's vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

有了要学习的数据，要创建的AI和要验证的湿实验室，Absci每周可以筛选数十亿个细胞，使其在短短六周内从AI设计的抗体转变为湿实验室验证的候选者。Absci的愿景是为每个人提供突破性的治疗方法，只需点击一个按钮。

Absci's headquarters is in Vancouver, WA, its AI Research Lab is in New York City, and its Innovation Center is in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube..

Absci的总部位于华盛顿州温哥华，其AI研究实验室位于纽约市，其创新中心位于瑞士祖格。访问www.absci.com，在LinkedIn（@absci）、X（Twitter）（@Abscibio）和YouTube上关注我们。。

SOURCE Viva Biotech Holdings

来源Viva Biotech Holdings